Present results and future perspectives in optimizing chronic myeloid leukemia therapy

被引：6
作者：
Carella, Angelo M. [1 ]
Saglio, Giuseppe [2 ,3 ]
Mahon, Xavier F. [4 ]
Mauro, Michael J. [5 ]
机构：
[1] Osped Policlin San Martino, Hematol & BMT Unit, Genoa, Italy
[2] Univ Torino, Dipartimento Sci Clin & Biol, Turin, Italy
[3] Osped Mauriziano Torino, Turin, Italy
[4] Univ Bordeaux, Bergonie Canc Inst, Bordeaux, France
[5] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, 1275 York Ave, New York, NY 10021 USA
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 06期
关键词：
TYROSINE KINASE INHIBITOR; COMPLETE MOLECULAR REMISSION; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC-PHASE; IMATINIB TREATMENT; FOLLOW-UP; DISCONTINUATION; DASATINIB; CML; IMPACT;
D O I：
10.3324/haematol.2017.182022
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：928 / 930
页数：3
相关论文
共 50 条
  • [21] Immunotherapy of chronic myeloid leukemia: present state and future prospects
    Vonka, Vladimir
    IMMUNOTHERAPY, 2010, 2 (02) : 227 - 241
  • [22] Treatment-free remission in patients with chronic myeloid leukemia
    Rea, Delphine
    Cayuela, Jean-Michel
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (04) : 355 - 364
  • [23] Third-line therapy for chronic myeloid leukemia: current status and future directions
    Cortes, Jorge
    Lang, Fabian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [24] Chronic Myeloid Leukemia: Current Perspectives
    Zhang, Yanming
    Rowley, Janet D.
    CLINICS IN LABORATORY MEDICINE, 2011, 31 (04) : 687 - +
  • [25] Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients
    Hiwase, Devendra K.
    Yeung, David T.
    White, Deborah L.
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (03) : 285 - 299
  • [26] Male Fertility and Fatherhood in Chronic Myeloid Leukemia: Current Understanding and Future Perspectives
    Elsabagh, Ahmed Adel
    Benkhadra, Maria
    Elmakaty, Ibrahim
    Elsayed, Abdelrahman
    Elsayed, Basant
    Elmarasi, Mohamed
    Abutineh, Mohammad
    Qasem, Nabeel Mohammad
    Ali, Elrazi
    Yassin, Mohamed
    CANCERS, 2024, 16 (04)
  • [27] Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents
    Kelly, Kevin
    Swords, Ronan
    Mahalingam, Devalingam
    Giles, Francis J.
    LEUKEMIA & LYMPHOMA, 2010, 51 (08) : 1399 - 1413
  • [28] Recommendations on monitoring and second-line therapy for chronic myeloid leukemia
    Hochhaus, A.
    Overkamp, F.
    Lange, T.
    Mohr, A.
    Ottmann, O.
    Coutre, P.
    Haferlach, T.
    ONKOLOGE, 2010, 16 (07): : 701 - 708
  • [29] Navigating the road toward optimal initial therapy for chronic myeloid leukemia
    Okimoto, Ross A.
    Van Etten, Richard A.
    CURRENT OPINION IN HEMATOLOGY, 2011, 18 (02) : 89 - 97
  • [30] Curing Chronic Myeloid Leukemia
    Rea, Delphine
    Rousselot, Philippe
    Guilhot, Joelle
    Guilhot, Francois
    Mahon, Francois-Xavier
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (02) : 103 - 108
12345